CCR5 antagonists for the treatment of HIV

Current Opinion in Investigational Drugs

Volumn 5, Issue 8, 2004, Pages 851-861

  Barber, Chris G ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

CCR5; Chemokine receptor antagonists; HIV; HIV fusion inhibitor; Viral entry

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHEMOKINE RECEPTOR CCR5;

ANIMAL; ANTIBIOTIC RESISTANCE; DRUG ANTAGONISM; DRUG INDUSTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REVIEW;

ANIMALS; ANTI-HIV AGENTS; DRUG INDUSTRY; DRUG RESISTANCE, VIRAL; HIV INFECTIONS; HUMANS; RECEPTORS, CCR5;

EID: 13344269098     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (102)

1. AIDS epidemic update, December 2003. World Health Organisation (2003):UNAIDS/03.39E.
2. Werber Y: HIV drug market. Nat Rev Drug Disc (2003) 2(7):513-514.
3. Richman DD: HIV chemotherapy. Nature (2001) 410(6831):995-1001.
4. Fumero E, Podzamczer D: New patterns of HIV-1 resistance during HAART. Clin Microbiol Infect (2003) 9(11):1077-1084.
5. De Clercq E: New anti-HIV agents and targets. Med Res Rev (2002) 22(6):531-565.
6. Weiss U: Nature insight. Nature (2001) 410:961.
7. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR: Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell (1996) 86(3):367-377.
8. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S et al: Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science (1996) 273(5283):1856-1862.
9. Proudfoot AEI: Chemokine receptors: Multifaceted therapeutic targets. Nat Rev Immunol (2002) 2(2):106-115.
10. Mueller A, Strange PG: The chemokine receptor CCR5. Int J Biochem Cell Biol (2004) 36(1):35-38.
11. Pozniak AI, Fätkenheuer G, Johnson M, Hoepelman IM, Rockstroh J, Goebel F, Abel S, James I, Rosario M, Medhurst C, Sullivan J et al: Effect of short-term monotherapy with UK-427857 on viral load in HIV-infected patients. ICAAC (2003) 43:Abs H-443.
12. Reynes J, Rouzier R, Kanouini T, Baillat V, Baroudy B, Keung A, Hogan C, Markowitz M, Laughlin M: Sch C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects. Conference on Retroviruses and Opportunistic Infections , Seattle, WA, USA (2002) 9:Abs1.
13. Price DA: CCR5 antagonists for HIV therapy. RSC-SCI Symposium, Receptors and Ion Channels, Cambridge, UK (2003).
14. Armour D, Wood A: The discovery of the CCR5 receptor antagonist, UK-427,857, A new treatment for HIV infection and AIDS. Prog Med Chem (2004) 42:manuscript submitted.
15. Dorr P, Macartney M, Rickett G, Smith-Burchnell S, Dobbs S, Mori J, Griffin P, Lok J, Irvine R, Westby M, Hitchcock C et al: UK-427857, a novel small molecule HIV entry inhibitor is a specific antagonist of the chemokine receptor CCR5. Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) 10:Abs 12.
16. Macartney M, Dorr PJ, Smith-Burchnell C, Mori J, Westby M, Hitchcock C, Perros M: In vitro antiviral profile of UK-427857: A novel CCR5 antagonist. ICAAC (2003) 43:Abs H-875.
17. Napier C, Dorr P, Gladue R, Halliday R, Leichman D, Machin I, Mitchell R, Nedderman A, Perros M, Roffey S, Walker D, Webster R: The preclinical pharmacokinetics of the anti-HIV CCR5 antagonist, UK-427857. Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) 10:Abs 546a.
18. Abel S, Van der Ryst E, Muirhead GJ, Rosario M, Edgington A, Weissgerber G: Pharmacokinetics of single and multiple oral doses of UK-427857 - a novel CCR5 antagonist in healthy volunteers. Conference in Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) 10:Abs 547.
19. Maeda K, Yoshimura K, Shibayama S, Habashita H, Tada H, Sagawa K, Mijakawa T, Aoki M, Fukushima D, Mitsuya H: Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5. J Biol Chem (2001) 276(37):35194-35200.
20. Maeda K, Ogata H, Harada S, Tojo Y, Miyakawa T, Nakata H, Takaoka Y, Shibayama S, Sagawa K, Daikichi F, Moravek J et al: Determination of binding sites of a unique CCR5 inhibitor AK602 on human CCR5. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2004) 11:Abs 540.
21. Demarest J, Adkison K, Sparks S, Shachoy-Clark A, Schell K, Reddy S, Fang L, O'Mara K, Shibayama S, Berrey M, Piscitelli S: Single and multiple dose escalation study to investigate the safety pharmacokinetics, and receptor binding of 873140, a novel CCR5 receptor antagonist in healthy subjects. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2004) 11:Abs 139.
22. Lynch CL, Hale JJ, Budhu RJ, Gentry AL, Mills SG, Chapman KT, MacCoss M, Malkowitz L, Springer MS, Gould SL, DeMartino JA et al: 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 4: Synthesis of N-1 acidic functionality affording analogues with enhanced antiviral activity against HIV. Bioorg Med Chem Lett (2002) 12(20):3001-3004.
23. Palani A, Shapiro S, Josien H, Bara T, Clader J, Greenlee W, Tagat J, Steensma R, McCombie S, Neustadt B, Pushpavanam P et al: Discovery of potent, orally bioavailable CCR5 antagonists - 2. Am Chem Soc Meeting (2001) 221:Abs 27.
24. Schurmann D, Rouzier R, Nougarede R, Reynes J, Fatkenheuer G, Raffi F, Michelet C, Tarral A, Hoffmann C, Kiunke J, Sprenger H et al: Sch D: Antiviral activity of a CCR5 receptor antagonist. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2004) 11:Abs 140.
25. Tagat J, McCombie S, Nazareno D, Steensma R, Labroli M, Baroudy B, Strizki J, Cox K: Discovery of potent, selective, and orally active CCR5 antagonists for the potential treatment of HIV infection. Am Chem Soc Meeting (2003) 225:Abs 26.
26. Tagat JR, McCombie SW, Nazareno D, Labroli MA, Xiao Y, Steensma RW, Strizki JM, Baroudy BM, Cox K, Lachowicz J, Varty G et al: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[4,6-dimethyl-5-pyrimidinyl)carbonyl]-4-[4-{2-methoxy-1(R)-4-(trifluoromethyl) -phenyl}ethyl-3(S)-methyl-1-pipera-zinyl]-4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist. J Med Chem (2004) 47(10):2405-2408.
27. Tagat JR, Steensma RW, McCrombie SW, Nazareno DV, Lin S-I, Neustadt BR, Cox K, Xu S, Wojcik L, Murray MG, Vantuno N et al: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4-methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl] ethyl]-1-piperazinyl]-piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. J Med Chem (2001) 44(21):3343-3346.
28. Boyle CD, Palani A: Structure-activity relationship studies: M2 and CCR5 receptor antagonists. Curr Top Med Chem (2003) 3(10):1155-1169.
29. Kazmierski W, Bifulco N, Yang H, Boone L, DeAnda F, Watson C, Kenakin T: Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors. Bioorg Med Chem (2003) 11(13):2663-2676.
30. Palani A, Shapiro S, Josien H, Bara T, Clader JW, Greenlee WJ, Cox K, Strizki JM, Baroudy BM: Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. J Med Chem (2002) 45(14):3143-3160.
31. McCrombie SW, Tagat JR, Vice SF, Lin S-I, Steensma R, Palani A, Neustadt BR, Baroudy BM, Strizki JM, Endres M, Cox K et al: Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. Bioorg Med Chem Lett (2003) 13(3):567-571.
32. Palani A, Shapiro S, Clader JW, Greenlee WJ, Blythin D, Cox K, Wagner NE, Strizki J, Baroudy BM, Dan N: Biological evaluation and interconversion studies of rotamers of Sch 351125, an orally bioavailable CCR5 antagonist. Bioorg Med Chem Lett (2003) 13(4):705-708.
33. Palani A, Shapiro S, Clader JW, Greenlee WJ, Vice S, McCombie S, Cox K, Strizki J, Baroudy BM: Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: Synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides. Bioorg Med Chem Lett (2003) 13(4):709-712.
34. Hale JJ, Budhu RJ, Mills SG, MacCross M, Malkowitz L, Siciliano S, Gould SL, DeMartino JA, Springer MS: 1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: Discovery of the pyrrolidine scaffold and determination of its stereochemical requirements. Bioorg Med Chem Lett (2001) 11(11):1437-1440.
35. Lynch CL, Willoughby CA, Hale JJ, Holson EJ, Budhu RJ, Gentry AL, Rosauer KG, Caldwell CG, Chen P, Mills SG, MacCoss M et al: 1,3,4- Trisubstituted pyrrolidine CCR5 receptor antagonists: Modifications of the arylpropylpiperidine side chains. Bioorg Med Chem Lett (2003) 13(1):119-123.
36. Lynch CL, Hale JJ, Budhu RJ, Gentry AL, Finke PE, Caldwell CG, Mills SG, MacCoss M, Shen D-M, Chapman KT, Malkowitz L et al: CCR5 antagonists: 3-(pyrrolidin-1-yl)propionic acid analogues with potent anti-HIV activity. Org Lett (2003) 5(14):2473-2475.
37. Castonguay LA, Weng Y, Adolfsen W, Di Salvo J, Kilburn R, Caldwell CG, Daugherty BL, Finke PE, Hale JJ, Lynch CL, Mills SG et al: Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: A molecular modelingguided mutagenesis study of the binding pocket. Biochemistry (2003) 42(6):1544-1550.
38. Shen D-M, Shu M, Mills SG, Chapman KT, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ, Kwei GY, Carella A et al: Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 1: Discovery and SAR study of 4-pyrazolylpiperidine side chains. Bioorg Med Chem Lett (2004) 14(4):935-939.
39. Shu M, Loebach JL, Parker KA, Mills SG, Chapman KT, Shen D-M, Malkowitz L, Springer MS, Gould SL, DeMartino JA, Siciliano SJ et al: Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 3: SAR studies on the benzylpyrazole segment. Bioorg Med Chem Lett (2004) 14(4):947-952.
40. Kumar S, Kwei GY, Poon GK, Iliff SA, Wang Y, Chen Q, Franklin RB, Didolkar V, Wang RW, Yamazaki M, Chiu S-HL et al: Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: Role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther (2003) 304(3):1161-1171.
41. Thoma G, Nuninger F, Schaefer M, Akyel KG, Albert R, Beerli C, Bruns C, Francotte E, Luyten M, MacKenzie D, Oberer L et al: Orally bioavailable competitive CCR5 antagonists. J Med Chem (2004) 47(8):1939-1955.
42. Shiraishi M, Aramaki Y, Seto M, Imoto H, Nishikawa Y, Kanzaki N, Okamoto M, Sawada H, Nishimura O, Baba M, Fujino M: Discovery of novel, potent and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem (2000) 43(10):2049-2063.
43. Iizawa Y, Kanzaki N, Takashima K, Miyake H, Tagawa Y, Sugihara Y, Baba M: Anti-HIV-1 activity of TAK-220, a small molecule CCR5 antagonist. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2004) 11:Oral-11.
44. Tremblay CL, Giguel F, Hicks JL, Chou TC, Lizawa Y, Sugihara Y, Hirsch MS: TAK-220, A novel small molecule inhibitor of CCR5 has favorable anti-HIV interactions with other antiretrovirals in vitro. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2004) 11:F-34.
45. Imamura S, Kurasawa O, Nara Y, Ichikawa T, Nishikawa Y, Iida T, Hashiguchi S, Kanzaki N, Iizawa Y, Baba M, Sugihara Y: CCR5 antagonists as anti-HIV-1 agents. Part 2: Synthesis and biological evaluation of N-[3-(4-benzylpiperidin-1-yl)propyl]-N,N′- diphenyl-ureas. Bioorg Med Chem (2004) 12(9):2295-2306.
46. Daoudi J-M, Greiner J, Aubertin A-M, Vierling P: New bicyclam-GalCer analogue conjugates: Synthesis and in vitro anti-HIV activity. Bioorg Med Chem Lett (2004) 14(2):495-498.
47. De Clercq E: The bicyclam AMD3100 story. Nat Rev Drug Disc (2003) 2(7):581-587.
48. Schols D, Vermeire K, Hatse S, Princen K, De Clercq E, Calandra G, Fricker S, Nelson K, Labrecque J, Bogucki D, Zhou Y et al: In vitro anti-HIV activity profile of AMD887, a novel CCR5 antagonist, in combination with the CXCR4 inhibitor AMD070. Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, USA (2004) 11:A-539.
49. Anon: Chemokine receptor antagonists as HIV entry inhibitors. Exp Opin Ther Pat (2004) 14:251-255.
50. Anon: Chemokine CCR5 antagonists incorporating a 4-aminopiperidine scaffold. Exp Opin Ther Pat (2003) 13:1469-1473.
51. Gao Z, Metz WA: Unraveling the chemistry of chemokine receptor ligands. Chem Rev (2003) 103(9):3733-3752.
52. Mastrolorenzo A, Scozzafava A, Supuran CT: Small molecule antagonists of chemokine receptors as emerging anti-HIV agents. Exp Opin Ther Pat (2001) 11:1245-1252.
53. Tomkowicz B, Collman RG: HIV-1 entry inhibitors: Closing the front door. Exp Opin Ther Targets (2004) 8(2):65-78.
54. Meanwell NA, Kadow JF: Inhibitors of the entry of HIV into host cells. Curr Opin Drug Disc Dev (2003) 6(4):451-461.
55. Song M, Breneman CM, Sukumar N: Three-dimensional quantitative structure-activity relationship analyses of piperidine-based CCR5 receptor antagonists. Bioorg Med Chem (2004) 12(2):489-499.
56. Debnath AK: Generation of predictive pharmacophore models for CCR5 antagonists: Study with piperidine- and piperazine-based compounds as a new clas of HIV-1 entry inhibitors. J Med Chem (2003) 46(21):4501- 4515.
57. Lee B, Sharron M, Blanpain C, Doranz BJ, Vakili J, Setoh P, Berg E, Liu G, Guy HR, Durell SR, Parmentier M et al: Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem (1999) 274(14):9617-9626.
58. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT et al: Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 78 (6):2790-2807.
59. Tsamis F, Gavrilov S, Kajumo F, Seibert C, Kuhmann S, Ketas T, Trkola A, Palani A, Clader JW, Tagat JR, McCombie S et al: Analysis of the mechanism by which the small-molecule CCR5 antagonists Sch351125 and Sch-350581 inhibit human immunodeficiency virus type 1 entry. J Virol (2003) 77(9):5201-5208.
60. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A et al: HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA (2002) 99(1):395-400.
61. Billick E, Seibert C, Pugach P, Ketas T, Trkola A, Endres MJ, Murgolo NJ, Coates E, Reyes GR, Baroudy BM, Sakmar TP et al: The differential sensitivity of human and rhesus macaque CCR5 to small-molecule inhibitors of human immunodeficiency virus type 1 entry is explained by a single amino acid difference and suggests a mechanism of action for these inhibitors. J Virol (2004) 78(8):4134-4144.
62. Schuitemaker H, de Roda Husman A-M: Chemokine receptors and the clinical course of HIV-1 infection. Trends Microbiol (1998) 6:244-249
63. Kuhmann SE, Pugach P, Kunstman KJ, Taylor J, Stanfield RL, Snyder A, Strizki JM, Riley J, Baroudy BM, Wilson IA, Korber BT et al: Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol (2004) 78(6):2790-2807.
64. Westby M, Smith-Burchnell C, Mori J, Lewis M, Mansfield R, Whitcomb J, Petropoulos CJ, Perros M: In vitro escape of R5 primary isolates from the CCR5 antagonist, UK-427857 is difficult and involves continued use of the CCR5 receptor. International HIV Drug Resistance workshop, Tenerife, Canary Islands, Spain (2004) 8:Abs S10.
65. Stoddart C, Xu S, Wojcik J, Riley J, Strizki J: Evaluation of in vivo HIV-1 escape from Sch-C (Sch 351125). Conference on Retroviruses and Opportunistic Infections, Boston, MA, USA (2003) 10:Abs A-614.
66. Mosier DE, Picchio GR, Gulizia RJ, Sabbe R, Poignard P, Picard L, Offord RE, Thompson DA, Wilken J: Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants. J Virol (1999) 73(5):3544-3550.
67. Dorr PK, Dobbs S, Rickett G, Lewis B, Macartney M, Westby M, Perros M: In vitro evaluation of prolonged CCR5 occupancy by small molecule antagonists with anti-HIV activity. ICAAC (2003) 43:Abs F-1462.
68. Fujii N, Nakashima H, Tamamura H: The therapeutic potential of CXCR4 antagonists in the treatment of HIV. Expert Opin Investig Drugs (2003) 12(2):185-195.
69. Juarez J, Bendall L, Bradstock K: Chemokines and their receptors as therapeutic targets: The role of the SDF-1/CXCR4 axis. Curr Pharm Des (2004) 10(11):1245-1259.
70. Menéndez-Arias L, Esté JA: HIV-resistance to viral entry inhibitors. Curr Pharm Des (2004) 10(15):1845-1860.
71. Esté JA: Virus entry as a target for anti-HIV intervention. Curr Med Chem (2003) 10(17):1617-1632.
72. Vermeire K, Schols D, Bell TW: CD4 down-modulating compounds with potent anti-HIV activity. Curr Pharm Des (2004) 10(15):1795- 1803.
73. Root MJ, Steger HK: HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des (2004) 10(15):1805-1825.
74. Wang H-GH, Williams RE, Lin P-F: A novel class of HIV-1 inhibitors that target the viral envelope and inhibits CD4 receptor binding. Curr Pharm Des (2004) 10(15):1785-1793.
75. Tremblay C: Effects of HIV-1 entry inhibitors in combination. Curr Pharm Des (2004) 10(15):1861-1865.
76. PFIZER LTD (Basford PA, Stephenson PT, Taylor SCJ, Wood A): Tropane derivatives as CCR5 modulators. WO-00084954 (2003).
77. ONO PHARMACEUTICALS CO LTD (Takaoka Y, Okamoto M, Genba Y, Ohie K): Novel crystals of triazaspiro[5.5]undecane derivative. WO-2004026874 (2004).
78. SCHERING-PLOUGH CORP (Palani A, Miller MA, Scott JD): Piperidine derivatives useful as CCR5 antagonists. US-00010008 (2004).
79. SCHERING-PLOUGH CORP (Baroudu BM, Clader JW, Josien HB, McCombie SW, McKittrick BA, Miller MW, Neustadt BR, Palani A, Smith EM, Steensma R, Tagat JR et al): Piperazine derivatives useful as CCR5 antagonists. US-00069252 (2003).
80. SCHERING-PLOUGH (Baroudu BM, Clader JW, Josien HB, McCombie SW, McKittrick BA, Miller MW, Neustadt BR, Palani A, Smith EM, Steensma R, Tagat JR et al): Piperidine derivatives useful as CCR5 antagonists. US-00004185 (2003).
81. SCHERING-PLOUGH CORP (Miller MW): CCR5 antagonists useful for treating AIDS. US-00008877 (2003).
82. SCHERING-PLOUGH CORP (Palani A, Miller MA, Scott JD): Piperidine derivatives useful as CCR5 antagonists. WO-00020716 (2003).
83. SCHERING-PLOUGH CORP (Leong W, Chen M, D'Sa B, Zhu M, Xiao T, Shi X, Tang S, Gala S, Goodman A, Nielsen CM, Lee GM et al): The synthesis of piperidine and piperazine compounds as CCR5 antagonists. WO-00084950 (2003).
84. SCHERING-PLOUGH CORP (Dunning L, Jaroch S, Kochanny M, Lee W, Lian X, Liang M, Lu S-F, Onuffer J, Phillips G, Wei G-P, Ye B): Substituted quinoline CCR5 receptor antagonists. WO-00002960 (2004).
85. MERCK & CO INC (Kim R, Chang J, Chapman KT, Mills SG): Modulators of CCR5 chemokine receptor activity. WO-03030898 (2003).
86. MERCK & CO INC (Willoughby CA, Matawan KR, Chapman KT, Mills SG, Shen D-M, Shu M): Pyrrolidine modulators of CCR5 chemokine receptor activity. US-06531484 (2003).
87. MERCK & CO INC (Finke RE, Loebach JL, Maccross M, Mills SG): Cyclopentyl modulators of chemokine receptor activity. US-06506777 (2003).
88. NORVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT GMBH (Albert R, Bruns C, Nuninger F, Streiff M, Thoma G, Zerwes H-G): Piperidine derivative chemokine receptor inhibitors useful for the treatment of inflammatory, allergic and autoimmune diseases. WO-02081449 (2002).
89. TAKEDA CHEMICAL INDUSTRIES LTD (Shiraishi M, Baba M, Aikawa K, Kanzaki N, Seto M, Iizawa Y): Bicyclic compound, production and use thereof. WO-03014105 (2003).
90. TAKEDA CHEMICAL INDUSTRIES LTD (Shiraishi M, Baba M, Seto M, Kanzaki N, Nishimura O): Cyclic compounds and uses thereof. US-06627651 (2003).
91. TAKEDA C HEMICAL INDUSTRIES LTD (Imamura S, Hashiguchi S, Hattori T, Nishimura O, Kanzaki N, Baba M, Sugihara Y): Cyclic amine compounds as CCR5 antagonists. US-20030114443 (2003).
92. TAKEDA CHEMICAL INDUSTRIES LTD (Imamura S, Hashiguchi S, Hattori T, Nishimura O, Kanzaki N, Baba M, Sugihara Y): Cyclic amine compounds as CCR5 antagonists. US-06562978 (2003).
93. ANORMED INC (Bridger GJ, Skerlj RT, Kaller A, Harwig C, Bogucki D, Wilson T, Crawford J, McEachern EJ, Atsma B, Nan S, Zhou Y et al): Novel heterocyclic compounds are modulators of chemokine receptors CXCR4 or CCR-5 useful for the treatment of HIV infection. WO-00222599 (2002).
94. ASTRAZENECA AB (Cumming J, Winter J): Novel piperidinyl derivatives as CCR5 modulators, useful for the treatment of autoimmune, proliferative or immunologically-mediated diseases including transplant rejection and AIDS. WO-2004018425 (2004).
95. ASTRAZENECA AB (Cumming J): Piperidine or 8-aza-bicyclo[3.2.1]oct-3-yl derivatives useful as modulators of chemokine receptor activity (especially CCR5). WO-03080574 (2003).
96. ASTRAZENECA AB (Tucker H): Preparation of N- piperidin-4-yl amides and ureas and their use as modulators of chemokine receptor activity (especially CCR5). WO-03042205 (2003).
97. ASTRAZENECA AB (Cumming J): Novel piperidine derivatives as modulators of chemokine CCR5 activity. WO-00042178 (2003).
98. ASTRAZENECA AB (Cumming J, Tucker H): Piperidine derivatives and their use as modulators of chemokine CCR5 activity. WO-03042177 (2003).
99. ASTRAZENECA AB (Burrows J, Cumming J): Novel 3-[4-(phenylacetylamino)piperidin-1-yl]propane derivatives as chemokine receptor modulators useful for treating immune and inflammatory and inflammatory disorders and HIV infection. WO-02079156 (2002).
100. ASTRAZENECA AB (Burrows J, Cumming J): Novel N-acyl-N-(2-[4-(2-phenylacetylamino)piperidin-1-yl] ethyl)aniline derivatives. WO-02076948 (2002).
101. SMITHKLINE B EECHAM CORP (Bondinell WE, Neeb MJ): Novel substituted benzanilides useful as CCR5 modulators for treating inflammatory and autoimmune diseases. WO-2004011427 (2004).
102. SMITHKLINE BEECHAM CORP (Bondinell WE, Neeb MJ): Novel substituted benzanilide compounds as CCR5 chemokine modulators useful for the treatment of inflammatory, autoimmune and other disorders. WO-2004010943 (2004).